Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.35 |
| ▸ | MAP4K3 | Q8IVH8 | 4/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | CTSC | P53634 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | GCK | P35557 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.32 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21774151 | 0.80 | CSNK2A1 (0.41) | QPCTBACE1CTSCCSNK2A1 | |
| SCHEMBL2403445 | 0.79 | SLC6A2 (0.47) | QPCTSLC6A2SLC6A4SLC6A3MAP4K3 | |
| SCHEMBL20924228 | 0.79 | HSD17B1 (0.47) | QPCTSLC6A2SLC6A4SLC6A3MAP4K3 | |
| SCHEMBL21774262 | 0.76 | CSNK2A1 (0.43) | QPCTBRD4CSNK2A1 | |
| SCHEMBL21774242 | 0.75 | EGLN2 (0.40) | QPCTMAP4K3TLR9TLR8TLR7 | |
| SCHEMBL21774172 | 0.73 | CHRM2 (0.37) | QPCTBRD4DRD1 | |
| SCHEMBL21774264 | 0.73 | AOC3 (0.45) | BRD4CSNK2A1DRD1 | |
| SCHEMBL26255820 | 0.72 | KDR (0.44) | SLC6A2SLC6A4SLC6A3MAP4K3 | |
| SCHEMBL20500609 | 0.71 | MAP4K4 (0.45) | QPCTBACE1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20924388 | 0.71 | HSD17B1 (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113613652-B | Benzimidazole compounds and their use in the treatment of alzheimer's disease or huntington's disease | 台湾卫生研究院 | 2022-08-23 | — | — | CN | disclosed |
| CN-113613652-A | Benzimidazole compounds and their use for treating alzheimer's disease or huntington's disease | 台湾卫生研究院 | 2021-11-05 | — | — | CN | disclosed |
| EP-3843724-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | National Health Research Institutes (TW) | 2021-07-07 | — | — | EP | disclosed |
| US-10584120-B1 | Benzimidazole compounds and use thereof for treating Alzheimer's Disease or Huntington's Disease | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2020-03-10 | — | — | US | disclosed |
| WO-2020047360-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2020-03-05 | — | — | WO | disclosed |
| US-20200071312-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | NATIONAL HEALTH RES INST (TW) | 2020-03-05 | — | — | US | disclosed |
| US-20200071312-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | NATIONAL HEALTH RES INST (TW) | 2020-03-05 | — | — | US | disclosed |
| WO-2020047360-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071312-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | GLUL, GLS2, GLS | QPCT 9/4885BACE1 66/4885SLC6A2 1465/4885 |
| US-10584120-B1 | Benzimidazole compounds and use thereof for treating Alzheimer's Disease or Huntington's Disease | GLUL, GLS2, GLS | QPCT 9/4885BACE1 66/4885SLC6A2 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.